SLC5A2 and Alzheimer disease: Here, we investigate sodium‐glucose cotransporter 2 (SGLT2) inhibition as a therapeutic strategy for AD using Enavogliflozin, a potent SGLT2 inhibitor, in the 5XFAD mouse model.